F A C T   S H E E T

For information contact:
Joni Morford, Communicore
714/721-8081
jmorford@communicore.com


ORQUEST, INC.


Orquest, Inc. was founded in 1994 to drive a new paradigm in orthobiologics by 
developing a portfolio of innovative and proprietary products for bone and 
cartilage regeneration.  Orthobiologics will enable physicians to restructure existing 
therapies in a less invasive manner thereby increasing patient satisfaction and 
reducing therapy costs.  Orquest's strategy is to engineer matrix-based products 
which promote the body's natural remodeling and tissue regeneration processes.  
Tailored to specific clinical indications, Orquest's products integrate the most 
effective biomaterials and growth factors.  The Company is targeting the major 
growth segments in orthopedics (spine and trauma).


Recent Milestones

* Initiated multi-center European clinical studies for spinal fusion.
* Completed strategic alliance with Spine-Tech, Inc. for minimally invasive spine 
system.
* Received $100,000 SBIR grant for cartilage regeneration.
* Initiated Hoechst Marion Roussel collaboration.
* Completed construction of GMP manufacturing facility.


Product Development

Healosª Orquest's first matrix-based product, mimics the inherent properties of 
natural bone - biochemically and architecturally.  Healos is a porous, open cell 
matrix formed from collagen fibrils coated with hydroxyapatite (the primary 
components of native bone).  Like natural bone, Healos is entirely replaced by newly 
formed bone as part of the natural healing process.  Healos was developed to 
eliminate a painful and expensive secondary surgery (autograft harvesting) 
routinely performed in spinal fusion.  Initial indications for Healos include spinal 
fusions and long-bone fractures. Healos is in clinical trials for spinal fusion in 
Europe; U.S. trials are expected to begin in late 1997.

Ossigelª Orquest's first injectable matrix, was developed to reduce the healing time 
in fresh fractures through a single administration.  Ossigel is a proprietary 
formulation of naturally occurring basic fibroblast growth factor (bFGF) with a 
hyaluronic acid (HA) gel.  Ossigel accelerates fracture healing by stimulating the 
formation of a stable callus, a critical stage in the early stabilization of a fracture.  
Ossigel is completing preclinical trials and human clinical trials in the U.S. are 
expected in the second half of 1997.


Technological Advantages

Orquest engineers its products from naturally occurring biomaterials that have 
excellent safety and acceptance records in FDA reviewed and FDA approved medical 
products.  Orquest's strength is in its ability to develop matrix-based products 
which harness the body's own natural capacity to regenerate and repair.  The 
Company's matrices are uniquely formulated to be rapidly resorbed by the body 
and replaced by newly formed natural bone.  In addition, Orquest's products 
demonstrate superior handling characteristics, a key requirement of physicians and 
orthopedic surgeons.


The Future

Orquest believes that additional matrix-based products will be necessary to meet the 
wide range of demands in the management of bone and cartilage regeneration.  
Orquest has several new proprietary matrices under development for targeted 
indications, such as cartilage regeneration. 


Management

S. Mitchell Seyedin, Ph.D., Founder, Chairman, and Chief Scientific Officer

Michael Sumner Estes, Ph.D., President, Chief Executive Officer

James W. Poser, Ph.D., Vice President, Research and Development

Steven R. Carlson, Vice President, Marketing, Sales, and Operations

James B. Andrews, CPA, Controller

Robert C. Spiro, Ph.D., Director, Bone and Cartilage Research

F. Jerry Volenec, Ph.D., Director, Product Development


Scientific Staff

The Company's team of prominent scientists and Scientific Advisory Board of 
leading orthopedic physicians is unique within the industry.


Investors

To date, Orquest has raised $12.5 million in funding from venture capital investors 
primarily provided by Asset Management, Charter Ventures, Institutional Venture 
Partners, Mayfield Fund, Sprout Capital, and Weiss, Peck and Greer.


General Background

Orquest currently employs 41 people and occupies 21,000 sq. ft. of leased space in 
Mountain View, California, USA.  The Company has the exclusive license to two 
U.S. issued patents and six pending patent applications.


End of document.